ID   GTL16R1
AC   CVCL_VS67
SY   GTL16 R1
DR   GEO; GSM686016
DR   GEO; GSM686035
DR   GEO; GSM686036
DR   Progenetix; CVCL_VS67
DR   Wikidata; Q93935412
RX   PubMed=22745804;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:91425; 2-[4-[3-(6-quinolinylmethyl)-5-triazolo[4,5-b]pyrazinyl]-1-pyrazolyl]ethanol (PF-04217903).
CC   Sequence variation: Gene fusion; HGNC; 1097; BRAF + HGNC; 30646; SND1; Name(s)=SND1-BRAF (PubMed=22745804).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from metastatic site: Liver.
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_7668 ! GTL-16
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 20-05-21; Version: 7
//
RX   PubMed=22745804; DOI=10.1371/journal.pone.0039653;
RA   Lee N.V., Lira M.E., Pavlicek A., Ye J., Buckman D., Bagrodia S.,
RA   Srinivasa S.P., Zhao Y., Aparicio S., Rejto P.A., Christensen J.G.,
RA   Ching K.A.;
RT   "A novel SND1-BRAF fusion confers resistance to c-Met inhibitor
RT   PF-04217903 in GTL16 cells through MAPK activation.";
RL   PLoS ONE 7:E39653-E39653(2012).
//